Liver Diseases  >>  MK-6325  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
MK-6325 / Merck (MSD)
NCT01329913: Safety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003)

Completed
1
36
RoW
MK-6325, Placebo to MK-6325
Merck Sharp & Dohme LLC
Hepatitis C
04/12
04/12

Download Options